Resectable Pancreatic Ductal Adenocarcinoma Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Resectable Pancreatic Ductal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Metastatic Pancreatic Ductal Adenocarcinoma+1 more
National Cancer Institute (NCI)43 enrolled26 locationsNCT05685602
Recruiting
Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+1 more
NRG Oncology356 enrolled242 locationsNCT06958328
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled7 locationsNCT07252232
Recruiting
Not Applicable

Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
British Columbia Cancer Agency200 enrolled1 locationNCT06574620
Recruiting
Phase 2

PULSAR in Systemic Therapy for Pancreatic Cancer

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaOligometastatic Pancreatic Ductal Adenocarcinoma
Samsung Medical Center47 enrolled1 locationNCT07269626
Recruiting
Phase 2

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+4 more
City of Hope Medical Center28 enrolled1 locationNCT04887805
Recruiting
Phase 1

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04484909
Recruiting
Phase 2

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

Stage I Pancreatic Cancer AJCC v8Localized Pancreatic AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma+2 more
Mayo Clinic130 enrolled1 locationNCT05518903
Recruiting

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy

Borderline Resectable Pancreatic Ductal AdenocarcinomaStage I Pancreatic Cancer AJCC v8Resectable Pancreatic Ductal Adenocarcinoma
Emory University87 enrolled1 locationNCT06595160
Recruiting
Phase 2

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Resectable Pancreatic Adenocarcinoma+2 more
Emory University36 enrolled1 locationNCT06423326
Recruiting
Phase 1

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Advanced Pancreatic Adenocarcinoma+1 more
City of Hope Medical Center19 enrolled1 locationNCT06454383